Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it.
ดาราตลกรุ่นใหญ่ชาวอังกฤษ เสียชีวิตด้วยวัย 65 ปี ด้วยอาการหัวใจวาย เซอร์สตีเฟน ฟราย นำการไว้ ...
Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial ...
Shares of Moderna Inc. fell sharply on Monday after the biotech firm projected a steep decline in 2025 revenues, falling below Wall Street expectations. The company, known for its COVID-19 vaccine ...
และถูกชกจนอาการสาหัส กำลังรักษาตัวอยู่ แต่อยู่ในสภาพไม่ได้สติ และหมอได้บอกให้ญาติทำใจ เพ ...
Moderna's partnership with Merck in personalized cancer therapies and promising Phase III trials support a speculative 'Buy' for long-term investors with high-risk tolerance. Despite a tough 2024 ...
In this article, we are going to take a look at where Moderna Inc. (NASDAQ:MRNA) stands against other firms end 2024 stronger with impressive gains. A lackluster trading persisted throughout the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback